Vimarsana
Biggest News Aggregation in the World

Substantial Body News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Substantial Body. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Substantial Body Today - Breaking & Trending Today

BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - Vimarsana News

BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA

Published: September 29, 2022

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Company resubmitted a Biologics License Application (BLA) to the U.S. Food...

Source: prnewswire.com
Related Topics:
United StatesHank FuchsDebra CharlesworthTraci MccartyEuropean CommissionDrug AdministrationBiomarin Pharmaceutical IncExchange CommissionWorldwide ResearchPrnewswire Biomarin Pharmaceutical IncEuropean UnionEuropean Medicines AgencyRobust Clinical ProgramSubstantial BodyPivotal PhaseOngoing PhaseGene TherapySevere HemophiliaMarin PharmaceuticalBiologics License ApplicationRegenerative Medicine Advanced TherapyBreakthrough Therapy DesignationBiomarin PharmaceuticalQuarterly Report
BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - Vimarsana News

BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA

Published: September 29, 2022

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the Company resubmitted a Biologics License Application (BLA) to the U.S. Food...

Source: prnewswire.com
Related Topics:
United StatesHank FuchsDebra CharlesworthTraci MccartyEuropean CommissionDrug AdministrationBiomarin Pharmaceutical IncExchange CommissionWorldwide ResearchPrnewswire Biomarin Pharmaceutical IncEuropean UnionEuropean Medicines AgencyRobust Clinical ProgramSubstantial BodyPivotal PhaseOngoing PhaseGene TherapySevere HemophiliaMarin PharmaceuticalBiologics License ApplicationRegenerative Medicine Advanced TherapyBreakthrough Therapy DesignationBiomarin PharmaceuticalQuarterly ReportBiomarin Pharmaceutical Inc